CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial. - Knoll RL; Brauny MM; Robert E; Cloos L; Waser L; Hilbert K; Ulmer N; Hillen B; Birkner T; Bartolomaeus TUP; Nitsche O; Jarquín-Díaz VH; et al. (Nature communications, 2025)